{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:53:52Z","timestamp":1753890832687,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Primaquine (PQ) is an antimalarial drug with the potential to reduce malaria transmission due to its capacity to clear mature<jats:italic>Plasmodium falciparum<\/jats:italic>gametocytes in the human host. However, the large-scale roll-out of PQ has to be counterbalanced by the additional risk of drug-induced hemolysis in individuals suffering from Glucose-6-phospate dehydrogenase (G6PD) deficiency, a genetic condition determined by polymorphisms on the X-linked<jats:italic>G6PD<\/jats:italic>gene. Most studies on G6PD deficiency and PQ-associated hemolysis focused on the G6PD A- variant, a combination of the two single nucleotide changes G202A (rs1050828) and A376G (rs1050829), although other polymorphisms may play a role. In this study, we tested the association of 20 G6PD single nucleotide polymorphisms (SNPs) with hemolysis measured seven days after low single dose of PQ given at the dose of 0.1 mg\/kg to 0.75 mg\/kg in 957 individuals from 6 previously published clinical trials investigating the safety and efficacy of this drug spanning five African countries. After adjusting for inter-study effects, age, gender, baseline hemoglobin level, PQ dose, and parasitemia at screening, our analysis showed putative association signals from the common G6PD mutation, A376G [\u2212log<jats:sub>10<\/jats:sub>(<jats:italic>p<\/jats:italic>-value) = 2.44] and two less-known SNPs, rs2230037 [\u2212log<jats:sub>10<\/jats:sub>(<jats:italic>p<\/jats:italic>-value] = 2.60), and rs28470352 [\u2212log<jats:sub>10<\/jats:sub>(<jats:italic>p<\/jats:italic>-value) = 2.15]; A376G and rs2230037 were in very strong linkage disequilibrium with each other (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>= 0.978). However, when the effects of these SNPs were included in the same regression model, the subsequent associations were in the borderline of statistical significance. In conclusion, whilst a role for the A- variant is well established, we did not observe an important additional role for other G6PD polymorphisms in determining post-treatment hemolysis in individuals treated with low single-dose PQ.<\/jats:p>","DOI":"10.3389\/fgene.2021.645688","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T07:02:24Z","timestamp":1617951744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["G6PD Polymorphisms and Hemolysis After Antimalarial Treatment With Low Single-Dose Primaquine: A Pooled Analysis of Six African Clinical Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Nuno","family":"Sep\u00falveda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Grignard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleta","family":"Mahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido J. H.","family":"Bastiaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Okebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam A.","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronner P.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna","family":"Affara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith C.","family":"Bougouma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume S.","family":"Sanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"N\u00e9bi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjerstin","family":"Lanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alassane","family":"Dicko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taane G.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Campino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice C.","family":"Eziefula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roly","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teun","family":"Bousema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Drakeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation.","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2271-z","article-title":"Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.","volume":"17","author":"Awandu","year":"2018","journal-title":"Malar. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pt.2010.08.005","article-title":"Consideration of ethics in primaquine therapy against malaria transmission.","volume":"27","author":"Baird","year":"2011","journal-title":"Trends Parasitol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190272","article-title":"Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials.","volume":"13","author":"Bastiaens","year":"2018","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Series B.."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/blood.v74.7.2550.2550","article-title":"Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-.","volume":"74","author":"Beutler","year":"1989","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/infdis\/jiy014","article-title":"Safety of single-dose primaquine in G6PD-deficient and G6PD-normal males in mali without malaria: an open-label, phase 1, dose-adjustment trial.","volume":"217","author":"Chen","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.15085","article-title":"Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia.","volume":"6","author":"Clarke","year":"2017","journal-title":"Elife"},{"key":"B9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S1473-3099(15)00479-X","article-title":"Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.","volume":"16","author":"Dicko","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","article-title":"Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.","volume":"14","author":"Eziefula","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02590-16","article-title":"Age, weight, and CYP2D6 genotype are major determinants of primaquine pharmacokinetics in African children.","volume":"61","author":"Gon\u00e7alves","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0581-y","article-title":"Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemetherlumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.","volume":"14","author":"Gon\u00e7alves","year":"2016","journal-title":"BMC Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00293","article-title":"Review of the quality control checks performed by current genome-wide and targeted-genome association studies on myalgic encephalomyelitis\/chronic fatigue syndrome.","volume":"8","author":"Grabowska","year":"2020","journal-title":"Front. Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1073\/pnas.85.11.3951","article-title":"Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-).","volume":"85","author":"Hirono","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-270","article-title":"Glucose-6-phosphate dehydrogenase polymorphisms and susceptibility to mild malaria in Dogon and Fulani, Mali.","volume":"13","author":"Maiga","year":"2014","journal-title":"Malar. J."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004960","article-title":"African glucose-6-phosphate dehydrogenase alleles associated with protection from severe malaria in heterozygous females in Tanzania.","volume":"11","author":"Manjurano","year":"2015","journal-title":"PLoS Genet."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1341-3","article-title":"Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.","volume":"15","author":"Mwaiswelo","year":"2016","journal-title":"Malar. J."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00538-19","article-title":"CYP2D6 polymorphisms and the safety and gametocytocidal activity of single-dose primaquine for Plasmodium falciparum.","volume":"63","author":"Pett","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng.3107","article-title":"Reappraisal of known malaria resistance loci in a large multicenter study.","volume":"46","author":"Rockett","year":"2014","journal-title":"Nat. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.dmpk.2018.08.004","article-title":"Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.","volume":"33","author":"Saito","year":"2018","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/infdis\/jix250","article-title":"Malaria host candidate genes validated by association with current, recent, and historical measures of transmission intensity.","volume":"216","author":"Sep\u00falveda","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-69","article-title":"Low density parasitaemia, red blood cell polymorphisms and Plasmodium falciparum specific immune responses in a low endemic area in northern Tanzania.","volume":"9","author":"Shekalaghe","year":"2009","journal-title":"BMC Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1128\/AAC.01135-09","article-title":"In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.","volume":"54","author":"Shekalaghe","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/infdis\/jix237","article-title":"A molecular assay to quantify male and female Plasmodium falciparum gametocytes: results from 2 randomized controlled trials using primaquine for gametocyte clearance.","volume":"216","author":"Stone","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41588-020-00713-x","article-title":"Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals.","volume":"52","author":"Surendran","year":"2020","journal-title":"Nat. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nature14962","article-title":"The UK10K project identifies rare variants in health and disease.","volume":"526","author":"Walter","year":"2015","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-424","article-title":"Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting.","volume":"11","year":"2012","journal-title":"Malar. J."},{"journal-title":"Updated WHO Policy Recommendation: Single Dose Primaquine as a Gametocytocide in Plasmodium Falciparum Malaria.","year":"2012","key":"B29"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.645688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T23:19:43Z","timestamp":1724800783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.645688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":29,"alternative-id":["10.3389\/fgene.2021.645688"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.645688","relation":{},"ISSN":["1664-8021"],"issn-type":[{"type":"electronic","value":"1664-8021"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"645688"}}